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Abstract
Invasive fungal infections caused by rare ﬁlamentous fungi constitute a signiﬁcant cause of morbidity and mortality in patients with defec-
tive immune responses. Despite the advent of new antifungal agents, the problem is escalating as the number of susceptible hosts
increases and virulent, more resistant fungal strains emerge. There is evidence that reconstitution of the host immune function is a
major contributor to the resolution of these infections. Therapeutic modalities aimed at increasing phagocyte numbers, such as granulo-
cyte transfusions, stimulating the immune response, such as administration of haematopoietic growth factors and other proinﬂammatory
cytokines, or indirectly augmenting immune function have shown promising results in the preclinical setting. Because of the rarity of the
infections, multicentre clinical trials are needed to demonstrate the efﬁcacy and safety of the new immunomodulating approaches.
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Introduction
Invasive fungal infections constitute an important cause of
morbidity and mortality, especially in immunocompromised
patients. Although Candida spp., Aspergillus spp. and Cryptococ-
cus neoformans are responsible for the bulk of invasive fungal
infections, other less common but problematic fungal patho-
gens also cause signiﬁcant morbidity and mortality [1]. Among
the emerging pathogens with worldwide distribution that are
appearing with increasing frequency are the group of non-sep-
tate Mucormycotina [2], and septate ﬁlamentous fungi (such
as Fusarium spp. and Scedosporium spp.) [1]. These fungal
pathogens mainly affect immunocompromised hosts, such as
neutropenic patients with haematological malignancies, recipi-
ents of haemotopoietic stem cell transplants (HSCTs) or solid
organ transplants, patients with diabetes mellitus and
ketoacidosis, premature infants, and patients with iron over-
load [1,2]. Although conventional antifungal therapy remains
the treatment of choice, it is becoming more difﬁcult to
successfully manage these emerging invasive fungal infections.
Among the factors that complicate the efﬁcacy of antifungal
treatment of these pathogens are the inherent resistance of
these fungi (Fusarium spp. and Scedosporium spp. are innately
resistant to most available antifungal agents), the appearance
of resistant fungal strains, the adverse effects associated with
antifungal chemotherapy, and the failure of antifungal therapy
to sterilize infected organs [3–5]. Therefore, given the limita-
tions of the current antifungal armamentarium, approaches
that target the host through manipulations to augment the
host immune response could provide a helpful supplement to
conventional treatment options.
In this review, we summarize the current state of knowl-
edge about the immunotherapeutic options for mucormyco-
sis, scedoporiosis, and fusariosis.
Mucormycosis (zygomycosis)
Mucormycosis is caused by fungi of the order Mucorales and
the family Mucoraceae [6]. In the recent reclassiﬁcation, all
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of the agents of mucormycosis have been placed under the
subphylum Mucormycotina [7]. Rhizopus, Mucor and Lichthei-
mia (formerly Absidia) are the most common genera causing
mucormysosis, accounting for 70–80% of all cases, whereas
Cunninghamella, Apophysomyces, Saksenaea, Rhizomucor, Coker-
omyces, Actinomucor and Syncephalastrum are responsible for
<1–5% of reported cases [8]. Mucormycosis is a life-threat-
ening infection that typically occurs in immunocompromised
hosts, such as those who have received HSCTs or solid
organ transplants, patients with neutropenia or malignancies,
and patients with diabetes mellitus [6,9,10].
Successful treatment of mucormycosis requires early diag-
nosis, reversal of underlying predisposing risk factors, surgical
debridement, and prompt administration of antifungal agents
[11]. Despite aggressive surgical and polyene antifungal treat-
ment, the mortality rate of mucormycosis is exceedingly high
[6,9,10]; therefore, improvement of the host response to
infection appears to be a critical factor inﬂuencing prognosis.
Clinical data have consistently underscored the impor-
tance of neutrophils in the development and outcome of mu-
cormycosis, especially in haematological patients [12]. In all
of the reported mucormycosis cases, resolution of neutrope-
nia was correlated with signiﬁcant improvement [13–17]. In
this regard, granulocyte transfusion therapy (GTT) repre-
sents a logical approach, being aimed at correcting quantita-
tive defects in patients with prolonged neutropenia or
defects in neutrophil function and severe fungal infections
[18]. With the advent of human recombinant myeloid col-
ony-stimulating factors (CSFs), GTT showed better clinical
efﬁcacy in the therapeutic and prophylactic settings [19].
GTT in patients with invasive fungal infections has not been
evaluated in prospective randomized clinical trials; however,
clinical data from small case series and case reports have
demonstrated good clinical efﬁcacy and safety in difﬁcult-to-
treat infections [20]. Particularly in patients with mucormy-
cosis, the current experience with GTT is limited to spo-
radic case reports [21–24]. It is of note that, in a series of
patients with haematological malignancies and life-threatening
infections during neutropenia, including ﬁve mucormycosis
cases, not a single reactivation occurred under prophylactic
GTT [22].
Speciﬁc proinﬂammatory cytokines, such as granulocyte
CSF (G-CSF), granulocyte–macrophage CSF (GM-CSF), and
interferon (IFN)-c, are critical components of the host
defence, promoting upregulation of chemotaxis, phagocyto-
sis, respiratory burst, and/or degranulation of neutrophils,
monocytes, and macrophages [25]. In vitro immunopharma-
cological studies and experiments in animal models have
shown that neutrophil antifungal activity against different
Zygomycetes species can be augmented by IFN-c or GM-
CSF alone or in combination with certain antifungal agents
(liposomal amphotericin B or voriconazole) [26–28]. Despite
the promising preclinical evidence that IFN-c and CSFs
could enhance the host immune response against mucormy-
cosis, administration of these cytokines as adjunctive ther-
apy has only been reported in case reports and small
uncontrolled series [29–33]. In a literature review of 925
reported mucormycosis cases, 15 of 18 (83%) patients who
received adjunctive treatment with G-CSF showed a favour-
able clinical response [9]. Recent reviews of paediatric cases
with mucormycosis revealed that cytokine administration
could be considered as adjunctive therapy; however, there
was no evidence-based clinical effect [34–36]. Overall, cyto-
kine support appeared to shorten the duration of neutrope-
nia and, in concert with liposomal amphotericin B, provided
beneﬁt to immunocompromised patients with mucormyco-
sis. However, with the currently available data, it is impossi-
ble to deﬁne precisely the contribution of cytokine therapy
to the successful outcome of these cases, as the ﬁndings
are limited by publication bias and the multiple medical and/
or surgical interventions instituted concomitantly in each
case.
Another adjunctive therapeutic modality with an immuno-
modulating effect that is used for mucormycosis is hyperbaric
oxygen (HBO). Administration of HBO for mucormycosis
has been described since the 1970s [37,38]. HBO has been
shown to have direct fungicidal activity, owing to the produc-
tion of oxygen-based free radicals and, thus, indirect immu-
nomodulating antimicrobial properties, including correction
of lactic acidosis, restoration of phagocytosis, augmentation
of the oxidative burst by neutrophils, and enhancement of
the antifungal action of amphotericin B. Additionally, HBO
increases the rate of tissue healing, by increasing the levels
of growth factors that promote angiogenesis [39,40]. A
review of the literature that identiﬁed 28 mucormycosis
cases adjunctively treated with HBO showed that HBO was
particularly beneﬁcial in diabetic patients (94% survival),
whereas the effectiveness of this treatment was doubtful in
patients with haematological malignancies or bone marrow
transplants [39]. Clinical data from single centres showed
that HBO treatment was a beneﬁcial adjunct in the treat-
ment of invasive fungal infections, including mucormycosis
[38,41]. In conclusion, considering the pathophysiology of
mucormycosis, HBO appears to be a potentially attractive
treatment adjunct. However, current evidence does not sup-
port HBO use as the standard of care in mucormycosis
cases; therefore, its use should be considered on an individ-
ual basis.
Given the central role of iron metabolism in microbial
pathogenesis, the use of effective iron chelators has been
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proven to be an effective adjunctive antifungal therapy against
mucormycosis [42]. Whereas deferoxamine predisposes
patients to Rhizopus infection [43] by acting as a siderophore
[44], deferasirox is fungicidal in vitro, signiﬁcantly improves
survival and decreases tissue fungal burden in diabetic keto-
acidotic or neutropenic mouse models [45]. In addition, def-
erasirox undergoes a synergistic interaction with liposomal
amphotericin B and enhances the host inﬂammatory
response against zygomycetes [45]. In an open-label study,
ﬁve of eight patients with mucormycosis treated with defer-
asirox in combination with other antifungal therapy showed
improvement by the end of deferasirox therapy, without
experiencing serious adverse events [46]. There are case
reports with either success [47,48] or failure [49] after sal-
vage deferasirox treatment. Nevertheless, the precise clinical
effects of deferasirox are confounded by concurrent treat-
ments and various underlying comorbidities in each patient
[47–49]. A prospective, phase II, randomized, double-blind,
placebo-controlled study of the safety and tolerability of
adjunctive deferasirox therapy in patients being treated with
liposomal amphotericin B for mucormycosis was completed
in December 2010, and the results are pending (DEFEAT-
Mucor study, ClinicalTrials.gov NCT00419770).
Immunosuppressive agents such as cyclosporin, tacrolimus
and sirolimus show synergy in vitro with various azoles (posa-
conazole, itraconazole, and ravuconazole), amphotericin B or
caspofungin against zygomycetes [50,51]. Whether these
ﬁndings are of clinical relevance remains to be veriﬁed in
clinical trials [5].
Statins, in addition to their lipid-lowering properties, have
pleiotropic immunomodulating functions that, in regard to
sepsis or infection, have a beneﬁcial effect for the host.
Although the mechanisms through which statins modulate
immune and inﬂammatory responses are largely unknown, it is
believed that they reduce the overall magnitude of the
systemic response rather than targeting individual inﬂamma-
tory mediators [52]. Statins have fungicidal activity against
zygomycetes, and supporting this is the observation that while
the prevalence of diabetic patients increased, the number of
mucormycosis cases in patients with diabetes decreased, a
phenomenon that coincided with the widespread use of statins
in these patients [53]. In fact, statins induce apoptosis-like cell
death in Mucor racemosus [54], and in vitro data have shown
that lovastatin has activity against a range of zygomycetes and
a synergistic effect with voriconazole [55]. It seems that each
statin has different effect against zygomycetes, and that differ-
ent zygomycetes might have different susceptibilities to the
same statin [56–58]. These ﬁndings provide the rationale for
further work on the effects of statins in the clinical setting.
Scedosporiosis
The genus Scedosporium includes two hyphomycetes of
emerging medical importance, Scedosporium apiospermum and
Scedosporium proliﬁcans. Pseudallescheria boydii is the teleo-
morph (sexual state), distinguished from its anamorph (asex-
ual state) S. apiospermum [1]. Over the years, both states
have undergone several sequential name changes, having
been referred to as Petriellidium boydii, Allescheria boydii, Pseud-
allescheria sheari, and Monosporium apiospermum [59].
Treatment of Scedosporium infections is particularly chal-
lenging, because of the resistance of the fungus to many anti-
fungal agents; thus, on many occasions, salvage treatment
options are required. The extremely poor prognosis of sce-
dosporiosis, especially in immunocompromised patients,
underlines the importance of reconstitution of the patient’s
immune status [4].
In vitro studies have shown that antifungal agents collaborate
with host defences against Scedosporium spp. For example,
amphotericin B lipid complex displays a signiﬁcant additive
effect with neutrophils against S. proliﬁcans and S. apiospermum
in vitro [60]. Similarly, triazoles in combination with neutrophils
cause a signiﬁcant additive increase in the damage to
S. proliﬁcans and S. apiospermum hyphae. Furthermore, under
certain conditions, synergism has been noted between triaz-
oles and neutrophils against S. proliﬁcans hyphae. It is of note
that the synergistic activity has been observed at low concen-
trations of the antifungal agents used. This ﬁnding may be of
particular importance, especially in immunocompromised
patients, when a triazole reaches its trough level in plasma,
when such synergy may prevent fungal regrowth [61]. Regard-
less of the mechanisms behind these collaborative effects, the
ﬁndings from these studies support the concomitant adminis-
tration of antifungal agents and granulocyte transfusions to
persistently neutropenic patients with invasive scedosporiosis.
However, to date, no cases of scedosporiosis have been
reported that have been treated with granulocyte transfusions.
Among the cytokines studied that enhance neutrophil anti-
fungal activity against Scedosporium spp. are IFN-c and GM-
CSF [62]. Treatment of neutrophils with the combination of
IFN-c and GM-CSF enhanced neutrophil activity against Sce-
dosporium spp., whereas each cytokine alone had no effect.
Despite the poor effect of either cytokine alone on the neu-
trophil oxidative burst after 22 h, the combined treatment
showed enhancement of the oxidative burst in response to
opsonized S. apiospermum hyphae. Similarly, after incubation
with cytokines for 2 h, only the combination signiﬁcantly
enhanced the oxidative burst against serum-opsonized and
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non-opsonized hyphae of Scedosporium spp. Thus, in this
study it was demonstrated that IFN-c and GM-CSF exhibit a
signiﬁcant time-dependent and species-dependent ability to
enhance neutrophil activity against Scedosporium spp. [62].
Ortoneda et al. [63], in an immunosuppressed murine
model of invasive infection by S. proliﬁcans, demonstrated
modest efﬁcacy of liposomal amphotericin B at 10 mg/kg per
day combined with G-CSF. Subsequent studies showed that
liposomal amphotericin B at very high doses (40 mg/kg per
day) combined with G-CSF did not signiﬁcantly improve sur-
vival [64]. Interestingly, administration of G-CSF alone
showed no beneﬁt as compared with the control group
[63,64]. In an immunocompetent murine model of dissemi-
nated S. proliﬁcans infection, it has been shown that posaco-
nazole and GM-CSF have a combined effect in damaging
S. proliﬁcans hyphae ex vivo. However, when posaconazole
and GM-CSF were administered to mice with invasive infec-
tion caused by S. proliﬁcans, they had selective beneﬁcial
effects on the burdens in certain organs but gave no addi-
tional survival beneﬁt [65]. Despite the limited clinical expe-
rience [66], administration of proinﬂammatory cytokines,
especially in neutropenic patients with scedosporiosis, may
be worthy of consideration.
Fusariosis
Fusarium spp. are common soil saprophytes to which humans
are frequently exposed. Fusarium spp. that are frequently
implicated in human disease are Fusarium solani, Fusarium oxy-
sporum, and Fusarium moniliforme [3]. Fusarium infections in
immunocompetent patients are usually superﬁcial or limited
to a single organ, whereas in immunosuppressed hosts
(HSCT recipients, and patients with severe or prolonged
neutropenia) fusariosis is invasive and disseminated [3,67].
The latter form of fusariosis can be life-threatening, as Fusari-
um spp. are among the most drug-resistant fungi. Treatment
of disseminated infection requires systemic antifungal ther-
apy, surgical debridement of infected tissues, if possible, and
immunotherapy [67].
Although the use of immunotherapeutic agents is not
established in fusariosis management, there are preclinical
data supporting their utility. Amphotericin B formulations
(deoxycholate and lipid formulations) at clinically relevant
concentrations have been shown in ex vivo studies to have
immunomodulatory effects on human neutrophils and mono-
cytes [68] and on rabbit pulmonary macrophages [69] in
response to F. solani. Similar ex vivo studies have demon-
strated that interleukin (IL)-15 plays an important role in the
immunomodulation of host responses against Fusarium spp.
In particular, IL-15 signiﬁcantly enhanced neutrophil-mediated
damage of Fusarium spp., and this effect was attributed, at
least in part, to the increased release of IL-8 [70]. The utility
of IL-15 as an adjunct to conventional treatment of fusariosis
has not been evaluated in the clinical setting; however, con-
sidering the low incidence of fusariosis and the marginal efﬁ-
cacy of conventional antifungal treatment, these ﬁndings
could be of value.
In a retrospective study of invasive Fusarium infections in
patients with haematological malignancies, a favourable
response was associated with CSF-elicited GTT [71]. Simi-
larly, in a prospective study of neutropenia-related fungal
infections, including three Fusarium infections, GTT was pro-
ven to be safe and effective. However, as the authors com-
ment, this is a temporary measure to be used only in
patients who are likely to recover from neutropenia, and it
is essential to start GTT soon after the onset of infection
[72]. There is also a case report where the combined use of
amphotericin B, GTT and GM-CSF was proven to be safe
and life-saving in a neutropenic patient with disseminated fus-
arial infection [73]. GTT has been administered in paediatric
patients to augment the host response against disseminated
fusariosis, with a successful outcome [74].
Conclusions
The up-to-date knowledge on immunotherapy for muco-
rmycosis, scedosporiosis and fusariosis is limited to ex vivo
experiments, animal studies, case reports, and small case
series. Randomized controlled clinical trials to provide evi-
dence of the efﬁcacy and safety of immunomodulatory fac-
tors are lacking, in all probability because of the relative
rarity of these infections. Some controversial issues, such
as dosing, timing of immunomodulatory intervention, and
the patient groups that would beneﬁt most, need to be
clariﬁed. Until randomized multicentre trials are per-
formed, adjunctive therapy with cytokines such as IFN-c,
GM-CSF, and G-CSF, or GTT, can be considered for
severe invasive infections caused by rare ﬁlamentous fungi,
especially when they are refractory to conventional anti-
fungal treatment and the patient is unable to mount an
immune response.
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